Skip to main content

Table 2 Clinical findings, side effects and treatment outcomes

From: Rivaroxaban for the treatment of cerebral venous thrombosis

Clinical findings

All patients (36)

Warfarin

(13)

Rivaroxaban (23)

P value

Duration of hospitalization (days)

 

16.77 ± 10.69

11.7 ± 7.61

0.133

Loss of consciousness

7 (19.44%)

  

0.382

 Yes

 

1 (7.7%)

6 (26.1%)

 No

 

12 (92.3%)

17 (73.9%)

Outcomes of treatment

 Minor bleeding

5 (15.63%)

2/10 (20%)

3/22 (13.63)

0.708

 Major bleeding

0

0

0

mRS

32a

10

22

> 0.999

 mRS (0 or 1)

28 (87.5%)

9 (90%)

19 (86.36%)

 mRS 2

4 (12.5%)

1 (10%)

3 (13.63%)

MRV (Recanalization)

19a

5

14

> 0.999

Recanalized

17 (93.75%)

5 (100%)

12 (85.71%)

 Complete

14 (84.37%)

4 (80%)

10 (83.33%)

 Partial

3 (9.38%)

1 (20%)

2 (16.67%)

 Not recanalized

2 (6.25%)

0

2 (14.29%)

  1. mRS modified ranking scale, MRV magnetic resonance venography. Quantitative statistics were shown using Mean and Standard Deviations, Mean ± (SD)
  2. a The number of the statistical population in the follow-up (mRS and MRV) was lower than the initial population due to not answering the phone call or unwillingness to participate in follow-up